版权说明 操作指南
首页 > 成果 > 详情

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Luo, Jichang;Liao, Wanying;Wang, Xue;Xu, Ran;Li, Wei;...
通讯作者:
Yang, B.;Jiao, L.
作者机构:
[Jiao, Liqun; Xu, Ran; Yang, Bin; Wang, Tao; Luo, Jichang; Ma, Yan] China Int Neurosci Inst China INI, Beijing, Peoples R China.
[Jiao, Liqun; Xu, Ran; Yang, Bin; Wang, Tao; Luo, Jichang; Ma, Yan] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing, Peoples R China.
[Liao, Wanying] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China.
[Wang, Xue] Capital Med Univ, Xuanwu Hosp, Med Lib, Beijing, Peoples R China.
[Li, Wei] Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Shandong, Peoples R China.
通讯机构:
[Yang, B.; Jiao, L.] C
China International Neuroscience Institute (China-INI)China
语种:
英文
关键词:
CLINICAL PHARMACOLOGY;Coronary heart disease;Lipid disorders;Protocols & guidelines;VASCULAR MEDICINE
期刊:
BMJ Open
ISSN:
2044-6055
年:
2022
卷:
12
期:
11
页码:
e062046
基金类别:
This work was supported by the Beijing Science and Technologic Project (Z201100005520019).
机构署名:
本校为其他机构
院系归属:
第一中医临床学院
摘要:
Introduction Atherosclerosis is the leading cause of cardiovascular disease (CVD), which is one of the most common causes of morbidity and mortality worldwide. Lipid accumulation and inflammation play a crucial role in the pathogenesis of atherosclerosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging lipid-lowering agent reported as a potential anti-inflammation effect in the prevention of CVD. However, the anti-inflammatory effect is still elusive. Therefore, a systematic review and meta-analysis is needed to...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com